A Study of Mircera in Renal Anemia Among Filipino Chronic Kidney Disease Patients
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy and safety of once monthly administration of Mircera in
Filipino patients with chronic kidney disease who are either on dialysis or predialysis, and
not receiving erythropoiesis stimulating agents.Patients will receive Mircera at a starting
dose of 0.6 micrograms/kg sc every 2 weeks, with dose adjustments until a target hemoglobin
level is achieved, and then dosing will continue every 4 weeks. The anticipated time on study
treatment is 3-12 months, and the target sample is <100 individuals.